Biology subjects

Canziani, G.

Publications and source records attributed to Canziani, G..

4 recordsLinked to original sources

bioRxiv2025

HIV Virion Capturing Liposomes for Therapeutic Vaccination

HIV infection currently has no effective cures and requires lifelong antiretroviral treatments. Cures have failed due to HIVs immune evasion and rapid mutation rate. Here we present a first in class HIV therapeutic vaccine, termed nanotrap therapeutic vaccines (NTVs) that are designed to capture circulating HIV virions and facilitate internalization by local antigen presenting cells. NTVs are modified liposomes that display the CD4 mimetic molecule, CJF-III-288, on their surfaces and have the TLR 7/8 agonist R848 loaded into their core. We show that NTVs can 1) bind gp120 and capture pseudoviral particles, 2) facilitate uptake by antigen presenting cells and 3) generate robust anti-HIV CD8 T cell immunity in transient infection mouse models. NTVs have translational potential to generate patient-specific HIV immunity.

bioengineering↗

bioRxiv2025

Decorin promotes nascent proteoglycan retention in cartilage matrix by strengthening collagen II-aggrecan integration

Cartilage extracellular matrix (ECM), a hydrated collagen II-aggrecan composite, undergoes dynamic turnover during both normal homeostasis and disease-associated remodeling. This study elucidates a crucial role for decorin in promoting the retention and stability of nascent aggrecan within this matrix. By applying bio-orthogonal click-labeling, we demonstrate that loss of decorin accelerates the release of nascent aggrecan under both physiological and inflammatory conditions, without affecting its preferred localization to the pericellular matrix. Conversely, supplementation with exogenous decorin mitigates inflammation-induced loss of nascent aggrecan, supporting its potential as a therapeutic target. At the molecular level, decorin exhibits strong binding affinity for aggrecan, and enhances aggrecan-aggrecan and aggrecan-collagen II interactions, reinforcing its direct role in integrating cartilage matrix constituents. Also, by binding to collagen II, decorin stiffens the collagen II fibril network, thereby strengthening the confinement effect that limits the diffusive loss of entrapped aggrecan. Notably, decorin does not alter chondrocyte transcriptomic profiles in vivo, emphasizing its primary role in maintaining matrix integrity through biophysical mechanisms rather than cell signaling. Together, these findings provide a mechanistic foundation for developing decorin-based biomaterials or gene therapies aimed at preserving or regenerating the cartilage matrix for improved outcomes in osteoarthritis.

biophysics↗

bioRxiv2025

Development of novel high-affinity nanobodies against EGFR for cancer therapy

The epidermal growth factor receptor (EGFR) is a member of a family of transmembrane tyrosine kinase receptors that plays a pivotal role in regulating diverse cellular processes such as cell proliferation, survival, migration, and differentiation. Aberrant activation of EGFR signaling has been implicated in various pathological conditions, particularly cancer, making it an attractive target for therapeutic intervention. While several anti-EGFR monoclonal antibodies have been developed and demonstrated their clinical value for the treatment of various solid tumors, smaller antibody fragments such as nanobodies (Nb) offer distinct advantages over conventional antibodies, including reduced immunogenicity and enhanced tumor penetration. In this paper, we report the isolation and characterization of two novel high-affinity Nb targeting EGFR. These Nb were identified and characterized using ELISA, flow cytometry, microscopy, and SPR. Furthermore, these Nb and bivalent Nb engineered from them were tested for their effects on cancer cell proliferation. We demonstrate that the novel Nb exhibit high affinity and potent anti-tumor activity in vitro in their bivalent form, positioning them as promising candidates for cancer treatment.

molecular biology↗

bioRxiv2021

A novel splice variant of human TGF-β type II receptor encodes a soluble protein and its Fc-tagged version prevents liver fibrosis in vivo.

We describe, for the first time, a new splice variant of the human TGF-{beta} type II receptor (T{beta}RII). The new transcript lacks 149 nucleotides, causing a frameshift with the appearance of an early stop codon, rendering a truncated mature protein of 57 amino acids. The predicted protein, lacking the transmembrane domain and with a distinctive 13 amino acid stretch in the C-terminus, was named T{beta}RII-Soluble Endogenous (T{beta}RII-SE). Binding predictions indicated that the novel 13 amino acid stretch interacts with all three TGF-{beta} cognate ligands and generate a more extensive protein-protein interface than T{beta}RII. T{beta}RII-SE and human IgG1 Fc-domain, were fused in frame in a lentiviral vector (Lv) for further characterization. With this vector, we transduced 293T cells and purified T{beta}RII-SE/Fc by A/G protein chromatography from conditioned medium. Immunoblotting revealed homogeneous bands of approximately 37 kDa (reduced) and 75 kD (non-reduced), indicating that T{beta}RII-SE/Fc is secreted as a disulphide-linked homodimer. Moreover, high affinity binding of T{beta}RII-SE to the three TGF-{beta} isoforms was confirmed by Surface Plasmon Resonance (SPR) analysis. Also, intrahepatic delivery of Lv.T{beta}RII-SE/Fc in a carbon tetrachloride-induced liver fibrosis model revealed amelioration of liver injury and fibrosis. Our results indicate that T{beta}RII-SE is a novel member of the TGF-{beta} signaling pathway with distinctive characteristics. This novel protein offers an alternative for the prevention and treatment of pathologies caused by the overproduction of TGF-{beta} ligands.

cell biology↗